Neisseria Meningitidis Infection - 19 Studies Found Completed : Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. : Meningococcal Disease : 2012-09-07 : Biological: MenACWY-CRM The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosacch Completed : Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers : Meningococcal Disease : 2013-11-11 : Biological: MenACWY-CRM MenACW Completed : Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults : Meningococcal Disease : 2007-11-16 : Biological: Men ACWY CRM A sin Completed : B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants : Meningococcal Disease : 2007-06-19 : Biological: MenACWY-CRM One do Withdrawn : A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger : Meningococcal Disease : 2011-02-08 Completed : One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age : Meningococcal Disease : 2010-06-04 : Biological: rMenB+OMV NZ Subjects will be assigned to a study group based on the group assignment in the Completed : Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers : Meningococcal Disease : 2009-02-18 : Biological: 1a - rMenB+OMV NZ and routine vaccines Completed : Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents : Meningococcal Disease : 2014-05-06 : Biological: MenABCWY Effective Completed : Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules : Meningococcal Disease : 2008-04-16 : Biological: rMenB+OMV NZ Other Completed : Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine : Meningococcal Disease : 2009-12-04 : Biological: Meningococcal (group B) multicomponent recombinant adsorbed vacc Next >>>
